Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GVAX pancreatic cancer vaccine |
| Synonyms | |
| Therapy Description |
GVAX pancreatic cancer vaccine is composed of irradiated pancreatic ductal adenocarcinoma (PDA) cells engineered to express GM-CSF, which induces T-cell response against PDA cells (PMID: 21217520, PMID: 32591464). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GVAX pancreatic cancer vaccine | GVAX pancreatic cancer vaccine is composed of irradiated pancreatic ductal adenocarcinoma (PDA) cells engineered to express GM-CSF, which induces T-cell response against PDA cells (PMID: 21217520, PMID: 32591464). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02243371 | Phase II | GVAX pancreatic cancer vaccine CRS-207 Cyclophosphamide | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | Completed | USA | 0 |